Metastases are the major cause of death from melanoma, a skin cancer that has the fastest rising incidence of any malignancy in the Western world. Molecular pathways that drive melanoblast migration in development are believed to underpin the movement and ultimately the metastasis of melanoma. Here we show that mice lacking P-Rex1, a Rac-specific Rho GTPase guanine nucleotide exchange factor, have a melanoblast migration defect during development evidenced by a white belly. Moreover, these P-Rex1−/− mice are resistant to metastasis when crossed to a murine model of melanoma. Mechanistically, this is associated with P-Rex1 driving invasion in a Rac-dependent manner. P-Rex1 is elevated in the majority of human melanoma cell lines and tumour tissue. We conclude that P-Rex1 has an important role in melanoblast migration and cancer progression to metastasis in mice and humans.
Melanoma is an aggressive skin cancer characterized by its resistance to chemotherapy. Its incidence has doubled over the past two decades in the Western world. Patients who have primary melanomas with a Breslow thickness >4 mm have a dramatically increased incidence of metastasis and reduced survival1. Progression to melanoma is driven primarily by oncogenic mutations of BRAF (50–60%) or NRAS (15–30%)2,3,4, but must be accompanied by further genetic and epigenetic changes in gene expression, most commonly the loss of tumour suppressors p16INK4A or PTEN5,6. Present treatments with conventional chemotherapies have had no impact on overall survival, with the BrafV600E-targeted therapy, vemurafenib (PLX4032), recently giving cause for encouragement7,8. However, there remains a deficit of effective treatment strategies for other melanoma types, while treatment resistance to vemurafenib has been reported in melanomas coexpressing NrasQ61K with oncogenic BrafV600E (refs 9 and 10).
PREX1 encodes the P-Rex1 Dbl family of Rho GTPase guanine nucleotide exchange factors (GEFs). Rho family small GTPases comprise a major branch of the Ras superfamily of small GTPases (for example, RhoA, Rac1 and Cdc42)11. P-Rex1 is a Rac-specific GEF stimulated by PI3K-stimulated phosphatidylinositol (3,4,5)-trisphosphate production and the β-gamma subunits of the heterotrimeric-G proteins (Gβγ), both of which bind to P-Rex1 (refs 12, 13, 14). It has also been identified as a transcriptional target of extracellular signal-regulated kinase (ERK) signalling across a panel of melanoma cell lines15. Rac, the main effector of P-Rex1 activity, is involved in the induction of actin-mediated membrane ruffling and lamellipodia formation at the leading edge of cell migration, and its aberrant activation has been implicated in tumour cell invasion and metastasis16,17.
P-Rex1 has not previously been characterized in genetically modified animal models of cancer that can genetically and pathologically recapitulate the human disease. Earlier studies using cancer cell lines have implicated a role in prostate, breast and ovarian cancer18,19,20,21. Here we demonstrate that P-Rex1 is necessary for migration of melanoblasts during mouse development, it facilitates metastasis formation in an NrasQ61K-driven mouse model of melanoma, and it is upregulated in human melanoma-derived cell lines and tissue.
P-Rex1-deficient mice have a white belly phenotype
We first investigated the in vivo relevance of P-Rex1 by further analyses of a P-Rex1−/− mouse22. We identified a 'white belly' phenotype with 100% penetrance in P-Rex1−/− mice on a pure C57BL6 background (Fig. 1a). The phenotype persisted when P-Rex1−/− mice were crossed with Tyr∷NrasQ61K/° transgenic mice (Tyr∷NrasQ61K/°; P-Rex1−/−), a major driver mutation in melanoma (Fig. 1a)23. Depigmentation affecting the feet was also observed in Tyr∷NrasQ61K/°; P-Rex1−/− mice (Fig. 1a). Tissue sections of bellies from P-Rex1−/− and Tyr∷NrasQ61K/°; P-Rex1−/− mice suggested that no melanocytes were present throughout the skin in the white belly area (Fig. 1b). Thus expression of NrasQ61K was not able to overcome the 'white belly' induced by ablation of PREX1.
P-Rex1 deficiency impairs normal melanoblast migration
The belly, feet and tail are the furthermost points of mouse melanoblast migration from the neural crest during embryogenesis. In line with this and the role of P-Rex1 in activation of Rac, we hypothesized that the areas of depigmentation in P-Rex1−/− mice predominantly represented a defect of melanoblast migration during embryogenesis, rather than an impaired proliferative capacity or inability to produce melanin pigment in adult melanocytes. To test this hypothesis, we first ensured the presence of PREX1 in melanoblasts (Fig. 2a).
To address whether melanoblast number or migratory behaviour was altered, we next analysed P-Rex1−/− and Tyr∷NrasQ61K/°; P-Rex1−/− mice that had been intercrossed with mice carrying the DCT-lacZ transgene, a melanoblast reporter line24. Melanoblast sparing of the feet and belly was apparent in both DCT-lacZ P-Rex1−/− and DCT-lacZ Tyr∷NrasQ61K/°; P-Rex1−/− mice at E15.5, excluding a defect in melanin production as a cause for their depigmentation (Fig. 2b,c).
Using a melanoblast migration assay, which compared differences in distal melanoblast migration at various points of development (Fig. 2d; Supplementary Fig. S1a), analysis of E13.5 and E15.5 embryos showed a statistical difference in melanoblast migration between DCT-lacZ P-Rex1−/− and DCT-lacZ P-Rex1+/+ mice (Fig. 2e; Supplementary Fig. S1b). This was not overcome by NrasQ61K/° expression (Fig. 2f; Supplementary Fig. S1b). Consistent with a migratory defect, melanoblasts on the flank of the DCT-lacZ P-Rex1−/− mice had fewer protrusions than DCT-lacZ P-Rex1+/+ controls (Fig. 2g,h).
A melanoblast cell number assay at E13.5 showed no difference in cell numbers between DCT-lacZ P-Rex1−/− and DCT-lacZ P-Rex1+/+ mice unless DCT-lacZ P-Rex1−/− mice were intercrossed with Tyr∷NrasQ61K/° mice (Supplementary Figs S2a,b). There was however a small but significant reduction of E15.5 cell numbers in DCT-lacZ P-Rex1−/− mice compared with DCT-lacZ P-Rex1+/+, and DCT-lacZ Tyr∷NrasQ61K/°; P-Rex1−/− compared with DCT-lacZ Tyr∷NrasQ61K/°; P-Rex1+/+ mice (Fig. 2i,j). This difference is likely to represent a proliferative deficit in P-Rex1−/− melanoblasts: cell death was not observed in E15.5 whole skin from P-Rex1+/+ or P-Rex1−/− mouse embryos, using a live ex vivo imaging technique that we have previously described (Supplementary Movies 1, 2, 3)25. Moreover, a significant reduction in E15.5 cell numbers was again seen in P-Rex1−/− embryos compared with P-Rex1+/+ controls using this technique (Supplementary Fig. S2c). Collectively, these results would be consistent with previous reports of a role for Rac in cell cycle control, as well as the proliferative defect observed when P-Rex1 was knocked down in breast cancer cell lines21,26,27. They suggest that a small proliferative defect is preceded by a marked migration defect in P-Rex1−/− mice.
P-Rex1 deficiency impairs metastasis in a melanoma mouse model
The imprint of past migratory behaviour of neural crest–derived melanocyte precursors has been suggested to confer a propensity of primary melanomas to establish distant metastases28,29,30. We therefore crossed P-Rex1−/− mice with a genetically modified model of metastatic malignant melanoma, Tyr∷NrasQ61K/°; INK4a−/− mice, to assess whether P-Rex1 may also be important for primary melanoma development and/or metastasis23.
Tyr∷NrasQ61K/°; INK4a−/−; P-Rex1+/+ mice developed primary melanoma and metastasis with a similar penetrance and latency to that previously described (Fig. 3a). Immunohistochemistry (IHC) was carried out on primary melanomas taken from P-Rex1+/+ and P-Rex1−/− mice to confirm P-Rex1 expression in tumours (Fig. 3b,c). Seven out of ten primary melanomas from P-Rex1+/+ mice showed staining for P-Rex1, compared with zero out of nine samples from P-Rex1−/− mice. All metastases from P-Rex1+/+ mice displayed immunoreactivity for P-Rex1 similar to that of MelanA (11 samples; lung, liver and brain; Fig. 3d).
Although Rac function has been shown to be required for primary squamous cell skin and lung tumour development31,32, we observed no difference in incidence, latency or tumour burden of primary melanomas between Tyr∷NrasQ61K/°; INK4a−/−; P-Rex1+/+ and Tyr∷NrasQ61K/°; INK4a−/−; P-Rex1−/− mice (Table 1; Fig. 3e,f). However, a significant reduction in melanoma metastasis was observed in the Tyr∷NrasQ61K/°; INK4a−/−; P-Rex1−/− cohort, with the number of metastases in control Tyr∷NrasQ61K/°; INK4a−/−; P-Rex1+/+ mice the same as previously reported (P=0.001; χ2-test; Table 1). Tyr∷NrasQ61K/o; INK4a−/−; P-Rex1−/− mice also had an improved overall survival (Fig. 3g). These data are consistent with the mouse melanoblast data, suggesting that P-Rex1 is a central component of migration and invasion.
Although we are unable to categorically exclude the possibility that our melanoma brain lesions are not primary melanocytic neoplasms of the central nervous system (CNS), a significant reduction in metastases was still seen when these lesions were excluded from our analysis (Table 1). Clearly they at least invade the brain parenchyma from either a blood-borne metastasis or the lepto-meningeal site of origin in primary CNS melanoma (Fig. 3d). In support of them being genuine metastases, no NrasQ61K mutations were observed in a previous study of human primary CNS melanoma33.
We next further explored the prometastatic role of endogenous P-Rex1 in melanoma by deriving melanocyte cell lines from the early pup skin of Tyr∷NrasQ61K/°; INK4a−/−; P-Rex+/+ and Tyr∷NrasQ61K/°; INK4a−/−; P-Rex1−/− mice. When injected via tail vein (TV) into C57BL6 mice, two out of four mice treated with Tyr∷NrasQ61K/°; INK4a−/−; P-Rex1−/− melanocytes were found to have metastases, compared with five out of five mice who were treated with Tyr∷NrasQ61K/°; INK4a−/−; P-Rex+/+ cells (Supplementary Table S1, Supplementary Fig. S3). A significant reduction in metastatic frequency was observed on histological analyses of the cohort injected with Tyr∷NrasQ61K/°; INK4a−/−; P-Rex1−/− melanocytes, with a clear reduction in metastatic tumour burden also seen (Supplementary Fig. S3a,b). Moreover, we observed a propensity of the Tyr∷NrasQ61K/°; INK4a−/−; P-Rex+/+ cells to metastasize to distant viscera (kidney, liver, heart and spleen), metastases that were not seen in the mice TV-treated with Tyr∷NrasQ61K/°; INK4a−/−; P-Rex1−/− cells (Supplementary Table S1, Supplementary Fig. S3c–g). Collectively, these results suggested that endogenous P-Rex1 can facilitate frequency, growth and organ spread of metastases in melanoma from the intravasation stage of the metastatic cascade.
These data in genetically modified models of cancer were also supported by analyses of immuno-deficient mice which were injected subcutaneously with a number of different human melanoma-derived cell lines (Supplementary Fig. S4a,b, Supplementary Table S2). In total, 17/24 cell lines developed tumours following injection, with 4/24 also forming metastases. Quantitative reverse transcription (RT)–PCR (Supplementary Methods) analysis revealed that, of the cell lines with P-Rex1 mRNA levels above the median ('high' P-Rex1), nearly all went on to develop tumours in immuno-deficient mice (Supplementary Figs. S4a). This included all mice that developed metastases, and notably, the two NrasQ61K and BrafV600E cell lines with the highest P-Rex1 mRNA levels both developed metastases. Statistical evaluation of these results confirmed that high P-Rex1 was 100% statistically sensitive for detecting those nude mice that developed metastases (Supplementary Table S3; P=0.005; χ2-test). P-Rex1 levels were highest in cell lines that form metastases after averaging P-Rex1 levels in cell lines that formed no tumours, tumours or metastases (Supplementary Fig. S4b). The lowest expression occurred in those cell lines that do not form tumours in immuno-deficient mice (Supplementary Fig. S4b).
P-Rex1 is upregulated and drives invasion in human melanoma
To test the relevance of our data to human melanomagenesis, we first examined the expression of P-Rex1 in established human melanoma cell lines derived from primary or metastatic disease. Compared with normal human melanocytes (NHM), there was marked P-Rex1 overexpression in nearly all of the cell lines (Fig. 4a). Moreover, the three cell lines with clearly the highest P-Rex1 expression (CHL1, SK-Mel119 and Mel224) were all derived from a metastatic source (Supplementary Table S4), supporting our above analysis that showed high P-Rex1 mRNA was sensitive for the development of metastases in TV-treated immuno-deficient mice (Supplementary Fig. S4).
We next assessed whether increased P-Rex1 activity in humans is also related to melanoma progression: this possibility was raised by both the sensitivity of high P-Rex1 mRNA for nude mouse metastasis development and the increased expression of P-Rex1 observed in melanoma-derived cell lines compared with normal melanocytes. IHC for P-Rex1 was performed on human tissue specimens from skin and melanoma: although P-Rex1 expression was not detectable in melanocytes in normal skin (3 out of 3 specimens), we consistently detected it in biopsies of primary melanomas (112 out of 141 specimens) and melanoma lymph node metastases (8 out of 9 specimens; Fig. 4b; Supplementary Fig. S5). These data provided further evidence of a role for P-Rex1 in human melanoma progression, and were consistent with our previous findings in mice.
One potential way that P-Rex1 could drive progression and metastatic spread is through an increased invasive capacity conferred by its RacGEF activity. To examine this, we knocked down endogenous P-Rex1 in the CHL1 human melanoma cell line, where P-Rex1 was upregulated (Fig. 4a). Consistently we observed that three-dimensional (3D) matrigel invasion was diminished following knockdown of endogenous P-Rex1 (Fig. 4c–e). This result was also reproducible in the WM793 human melanoma cell line used in our RT–PCR data (Supplementary Fig. S6a–c). As P-Rex1 is overexpressed in the majority of human melanoma cell lines, we used the previously described melanocyte cell line derived from early pup skin of Tyr∷NrasQ61K/°; INK4a−/−; P-Rex1−/− mice to examine invasion in a cell line where P-Rex1 is not endogenously expressed. These P-Rex1−/− cell lines, which were genetically manipulated to overexpress empty vector ('pLHCX'), failed to invade in 3D matrigel and organotypic assays unless they were re-constituted to express ectopic levels of P-Rex1 ('P-Rex1'; Fig. 4f–i). Expression of ectopic levels of GEF-dead P-Rex1 ('P-Rex1 GD') failed to phenocopy the invasive phenotype of cells with re-constituted wild-type P-Rex1, confirming the RacGEF activity of P-Rex1 as a downstream mechanism (Fig. 4f–i). Interestingly, ectopic expression of another RacGEF described in melanoma, TIAM1, also failed to phenocopy the invasion seen with P-Rex1 expression (Fig. 4f–h)34. These results showed that the RacGEF activity of P-Rex1 may have a unique role among RacGEFs: it functions as a vital component of invasion for cells of the melanocyte lineage, a mechanism by which it can drive melanoma progression and metastases.
Here we evaluated the role of a Rac-specific Rho GTPase GEF, P-Rex1, for the first time in a genetically modified animal model of cancer. In particular, we have examined its role in melanoma progression, invasion and metastasis. First, we showed that P-Rex1 has a role in progression with our human cell line and IHC analysis showing P-Rex1 upregulation in tumour compared with NHMs. Second, matrigel and organotypic invasion assays confirmed that P-Rex1 is a key component of invasion in both humans and mice, channelled through its RacGEF activity. Finally and most importantly, we have determined that genetic ablation of PREX1 impairs melanoma metastases in Tyr∷NrasQ61K; INK4a−/− mice. Taken together, these results confirm that P-Rex1 upregulation is an important component of melanoma progression, invasion and metastatic signalling, supporting the value of pharmacological inhibition of P-Rex1 activation of Rac for treatment of metastatic or high-risk primary melanomas.
Mechanistic experiments in our study have highlighted the key similarities between the molecular machinery involved in the movement of melanoblasts and that of metastatic melanoma cells. Genetic ablation of PREX1 impaired migration of melanoblasts, evidenced by a 'white belly' phenotype that reflected the diminished metastases seen in Tyr∷NrasQ61K; INK4a−/− mice. A potential pathophysiological link with incidence of metastases therefore fits the physiological role of P-Rex1 seen in melanoblast migration. Moreover, the predominant role of P-Rex1 in invasion and migration is reflected by its presence in motile melanoblasts and its upregulation in metastatic melanoma cell lines.
Other studies have previously suggested a role for P-Rex1 in prostate, breast and ovarian cancer18,19,20,21, with key similarities existing between our study and that of Sosa et al.19 in particular. Notably, this report identified P-Rex1 as having particular relevance to the specific ER+ (+/− ErbB2) subset of breast tumours. One key area to focus on next will be to assess whether the in vivo tumourigenic effects of P-Rex1 are specific to melanomas driven by oncogenic Nras, or reproducible in BrafV600E-driven tumours: this is a clear possibility given the identification of P-Rex1 as a transcriptional target of ERK signalling in melanoma15. These previous P-Rex1 cancer studies have also shown an effect on both primary tumour growth and lymph node metastases using xenotransplantation of human cancer cell lines into immuno-deficient mice. However, this technique often fails to recapitulate the characteristics of the original tumour they are meant to represent, and their use for informative studies of novel cancer target validation has become increasingly contentious35,36,37. A key advance in our study is therefore the characterization of P-Rex1 in animal models of cancer, which recapitulate the common human genetics of the disease.
Strategies for inhibiting RAS have long been a therapeutic challenge9. Our findings suggest that targeting P-Rex1 signalling might have great relevance to tumours driven or codriven by oncogenic RAS, with potential benefits extending to all melanomas10. There is limited but growing evidence that Rho GTPase guanine nucleotide exchange factors are tractable targets for the development of small-molecule inhibitors17. The lack of P-Rex1 expression in most other normal human cell types offers a clear therapeutic window and basis for selective cytotoxicity14,37.
Here we have identified P-Rex1 as a novel anticancer target in melanoma. Our experiments provide stringent preclinical validation of P-Rex1 in cancer using informative genetically defined mouse models that recapitulate common human mutations. Together with recent observations in other cancers18,19,20,21, we suggest that P-Rex1 is an important therapeutic target for the treatment of a diverse spectrum of human cancers.
Embryo analysis and β-galactosidase staining
All studies were conducted in accordance with UK home office guidelines. Time of gestation was calculated using noon on the day of detection of a vaginal plug as E0.5, but also noting and comparing the external appearance of the embryo. Embryos were dissected at E15.5 then fixed in 0.25% glutaraldehyde at 4 °C for 45 min on a rolling platform. Embryos washed in PBS at 4 °C for 15 min on a rolling platform, detergent washed (2 mM MgCl2, 0.01% Na-deoxycholate, 0.02% NP-40 in PBS) at room temperature three times (30 min, 15 min two times). β-Galactosidase substrate (1 M MgCl2, 0.02% NP-40, 0.01% Na-deoxycholate, 0.04% 5-bromo-4-chloro-3-indolyl-β-D-galactoside, 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6) was then added to the embryos, which were incubated in darkness overnight. Embryos were postfixed in 4% paraformaldehyde for 2 h at 4 °C.
For cell number assays, the area used for quantification of cell numbers represented the most proximal point of melanoblast migration from the neural crest which could be accurately assayed. Counting melanoblasts in more distal regions would have introduced a migrational component to the assay which we aimed to avoid.
Mouse treatment and survival cohorts
A total of 80 Tyr∷NrasQ61K/°; INK4a−/− and 10 C57BL6 mice were monitored for up to 18 months for the development of melanoma and signs of metastasis. All mice were checked thrice weekly for the development of malignant melanoma or any other pathology. End point criteria were melanomas ≥15 mm, ulcerating melanomas, cachexia, significant weight loss, or weakness and inactivity. Upon meeting these criteria, mice were euthanized. Mice were examined for the presence of frank metastasis upon dissection, but also visualization of haematoxylin-and-eosin (H&E)-stained sections for further identification of microscopic metastases. Organs/tumours were removed and fixed in 10% buffered formalin overnight at room temperature. Fixed tissues were paraffin embedded, and 5 mm sections were placed on sialynated/poly-L-lysine slides for immunohistochemical analysis. Lymph node metastases were not included in this analysis due to difficulty in distinguishing them from normal melanocyte populations that can be found in lymphoid tissue.
For TV-injections into C57BL6 mice, cultured cells were maintained in antibiotic-free media for 1 week before injection. Cells were detached with trypsin, then blocked through suspension in complete culture media supplemented with 10% fetal bovine serum (FCS). Cells subjected to two rounds of washing, involving centrifugation at 100 g for 5 min followed by resuspension in 1× Hanks' Balanced Salt Solution (HBSS). Cells were finally resuspended in HBSS to a concentration of 1×107 cells ml−1 and TV injected at 1×106 cells per animal in a volume of 100 μl.
For P-Rex1, serial sections were unmasked in 10 mM citric acid, pH 6.0, with boiling for 30 min. Remaining steps were carried out with Thermo ScientificUltraVision LP Detection System (Thermo Fischer Scientific). Primary antibody was incubated in the presence of 5% normal goat serum (Dako). Antigens were developed with Vector Red Alkaline Phosphatase Substrate Kit (Vector Labs). The following antibody dilutions were used: P-Rex1, 1:100; MelanA, 1:100. 'Positive' staining refers to any level of staining visualized.
Rabbit polyclonal raised against human P-Rex1 (HPA001927) and mouse monoclonal specific to β-actin (clone AC-15, A1978) were obtained from Sigma-Aldrich. Mouse monoclonal specific to Melan-A (clones DT101 + BC199, ab731) was obtained from Abcam Ltd.
A tissue microarray was performed on archival paraffin patient samples from St Vincent's University Hospital, Dublin, Ireland. Quadruplicate cores from 141 consecutive melanoma patients (1994–2007) were used to construct the tissue microarray. Further samples were received from Radboud University Medical Center, Nijmegen, the Netherlands. All patient specimens were used in accordance with institutional and national policies at the respective locations.
Statistical analyses in mice were carried out using Minitab version 15 for Windows. Cell migration, invasion and cell number differences were determined using Mann–Whitney test. Distinction of metastasis and primary melanoma incidence was achieved using χ2-testing. Survival differences were determined with log-rank testing. All P-values were considered significant at P⩽0.05. All appropriate value sets were tested for normality using a Kolmogorov–Smirnoff normality test.
NHMs were maintained in Mln254 medium (M-254-500, Cascade Biologics) supplemented with human melanocyte growth serum (S-002-5, Cascade Biologics) and penicillin/streptomycin at 100 U ml−1. Mel224, Mel505, SK-Mel 2, 5, 23, 119, 147 and 187, CHL-1, A375 and WM266.4 were maintained in Dulbecco's modified Eagle medium supplemented with 10% FCS, L-glutamine at 200 μM and penicillin/streptomycin at 100 U ml−1. SBCL2, Lu1205, WM852, MeWo, Dauv-1, Gerlach, 888mel, 501mel, MNT-1, WM 35, 278, 793, 902b, 1552c and 1789 were maintained in RPMI 1640 supplemented with 10% FCS and penicillin/streptomycin at 100 U ml−1.
For melanocyte isolation from mice, pup skin was dissected at P2 then placed in ice-cold PBS. Quickly it was cut into pieces and incubated in 1.5 ml of collagenase types 1 and 2 at 37 °C, 5% CO2 for approximately 25–50 min. Contents transferred into 10 ml wash buffer (1× HBSS, 1 mM CaCl2, 0.005% DNase) and centrifuged at 200 g for 5 min at room temperature. Sample resuspended in 2 ml dissociation buffer, placed in small Petri dish and incubated at 37 °C, 5% CO2 for 10 min. Thereafter, sample was put through an 18G then 20G needle and transferred into 10 ml wash buffer for 10 min. Supernatant centrifuged at 200 g for 5 min at room temp, pellet resuspended in 2 ml PBS, then re-centrifuged at 200 g for 5 min. Resuspended and maintained in RPMI 1640 medium supplemented with 10% FCS, L-glutamine at 200 μM and penicillin/streptomycin at 100 U ml−1.
siRNA treatments and RacGEF constructs
Stable cell lines expressing Myc-epitope tagged human P-Rex1 were generated by retroviral infection using the modified Retro-X retroviral expression system (Clontech). An HpaI restriction site, followed by Kozak consensus translation initiation site was introduced to the 5′ end of the coding sequence of myc-P-Rex1 (ref. 13), myc-P-Rex1 GEF-dead13 or myc-Tiam1 by PCR (5′-GTTAACCACCATGGAGCAGAAGCTGATC-3′), with a ClaI restriction site introduced to the 3′ end in the same reaction (P-Rex1/P-Rex1 GEF-dead: 5′-CCATCGATTCAGAGGTCCCCATCCACCGG-3′), with pCMV-P-Rex1, pCMV-P-Rex1 GEF-dead or pcDNA3.1-myc-Tiam1 used as template. In each case, the HpaI–ClaI DNA fragments produced were subcloned into HpaI and ClaI sites of the pLHCX retroviral expression vector. High-titre, replication-incompetent retroviral particles encoding the RNA of interest were produced in the Phoenix Ampho packaging line (Orbigen), for human target cells, and the Phoenix Eco packaging line (Orbigen) for murine target cells. Subsequent infection of target lines resulted in transfer of the coding region of interest, along with a selectable marker. Pooled cell lines stably expressing the construct of interest were isolated by selection with hygromycin-B (500 μg ml−1) over multiple passages. Control lines were infected with retroviral particles expressing an empty pLHCX control vector transcript, and subjected to an identical selection procedure. Expression of the ectopically introduced proteins of interest was determined by western blot and immunodetection with both epitope-tag-specific and protein-specific primary antibodies.
Transient knockdown of target proteins was achieved through consecutive rounds of liposome-mediated transfection with the appropriate small interfering RNA (siRNA) oligonucleotides, 48 h apart. Liposomal transfection reagent (301702, HiPerFect), non-targeting control oligonucleotides (1027281, AllStars Negative Control) and P-Rex1-specific oligonucleotides (SI00692405, Hs_PREX1_3; SI03144449, Hs_PREX1_5; SI03246383, Hs_PREX1_6) were obtained from Qiagen Ltd.
For inverted Matrigel invasion assays38, Matrigel protein matrix (BD Bioscience) was allowed to polymerize in Transwell permeable inserts (Corning Ltd) over a period of 60 min at 37 °C. Inserts were inverted, and cells seeded directly onto the filter surface in complete growth medium. Cells were then allowed to adhere over a period of 3 h at 37 °C, after which both non-adherent cells and residual growth medium were removed with three washes in appropriate serum-free medium. Finally, inserts were placed in serum-free tissue culture medium (containing 10% FCS) above the Matrigel matrix to function as a chemoattractant. In the case of siRNA-mediated transient knockdown experiments, invasion assays were prepared 24 h after the second round of lipofection. At 72-h postseeding, invasive cells that had entered Matrigel were stained with the fluorescent live-cell dye Calcein-AM, and visualized through confocal microscopy of optical sections obtained in the z-plane at 15 μm intervals. Quantification was with the Area Calculator plugin for ImageJ (http://rsbweb.nih.gov/ij/).
For organotypic invasion assays39, approximately 7.5×104 ml−1 primary human fibroblasts were embedded in a 3D matrix of rat tail collagen I. Rat tail tendon collagen solution was prepared by the extraction of tendons with 0.5 M acetic acid to a concentration of ∼2 mg ml−1. Detached, polymerized matrix (2.5 ml) in 35-mm Petri dishes was allowed to contract for approximately 6 days in complete media (DMEM, supplemented with 10% FCS; Invitrogen) until the fibroblasts had contracted the matrix to ∼1.5 cm diameter. Subsequently, Tyr∷NrasQ61K/°; INK4a−/−; P-Rex1−/− melanocytes, stably expressing either control vector, human P-Rex1 or a GEF-dead mutant of human P-Rex1, were seeded onto the prepared matrix in complete media (4×104 cells per assay) and allowed to grow to confluence for 5 days. The matrix was then mounted on a metal grid and raised to the air/liquid interface resulting in the matrix being fed from below with complete media that was changed every 2 days. After 15 days, the cultures were fixed with 4% paraformaldehyde and processed by standard methods for haematoxylin and eosin staining.
How to cite this article: C. R. Lindsay et al. P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat. Commun. 2:555 doi: 10.1038/ncomms1560 (2011).
Gray-Schopfer, V., Wellbrock, C. & Marais, R. Melanoma biology and new targeted therapy. Nature 445, 851–857 (2007).
Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
Kabbarah, O. et al. Integrative genome comparison of primary and metastatic melanomas. PLoS One 5, e10770 (2010).
Smalley, K. S. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J. Invest. Dermatol. 130, 28–37 (2010).
Chin, L., Garraway, L. A. & Fisher, D. E. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 20, 2149–2182 (2006).
Stahl, J. M. et al. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 63, 2881–2890 (2003).
Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599 (2010).
Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 876–878 (2010).
Flaherty, K. T. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin. Cancer Res. 12, 2366s–2370s (2006).
Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209–221 (2010).
Wennerberg, K., Rossman, K. L. & Der, C. J. The Ras superfamily at a glance. J. Cell Sci. 118, 843–846 (2005).
Barber, M. A. et al. Membrane translocation of P-Rex1 is mediated by G protein betagamma subunits and phosphoinositide 3-kinase. J. Biol. Chem. 282, 29967–29976 (2007).
Hill, K. et al. Regulation of P-Rex1 by phosphatidylinositol (3,4,5)-trisphosphate and Gbetagamma subunits. J. Biol. Chem. 280, 4166–4173 (2005).
Welch, H. C. et al. P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac. Cell 108, 809–821 (2002).
Shields, J. M. et al. Lack of extracellular signal-related kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res. 67, 1502–1512 (2007).
Rossman, K. L., Der, C. J. & Sondek, J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat. Rev. Mol. Cell Biol. 6, 167–180 (2005).
Vigil, D., Rossman, K. L., Cherfils, J. & Der, C. J. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat. Rev. Cancer 10, 842–857 (2010).
Qin, J. et al. Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis. Oncogene 28, 1853–1863 (2009).
Sosa, M. S. et al. Identification of the Rac-GEF P-Rex1 as an essential mediator ErbB signaling in breast cancer. Mol. Cell 40, 877–892 (2010).
Kim, E. K. et al. Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastases. Oncogene 30, 2954–2963 (2011).
Montero, J. C. et al. P-Rex1 participates in Neuregulin–ErbB signal transduction and its expression correlates with patient outcome in breast cancer. Oncogene 30, 1059–1071 (2011).
Welch, H. C. et al. P-Rex1 regulates neutrophil function. Curr. Biol. 15, 1867–1873 (2005).
Ackermann, J. et al. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res. 65, 4005–4011 (2005).
Mackenzie, M. A., Jordan, S. A., Budd, P. S. & Jackson, I. J. Activation of the receptor tyrosine kinase Kit is required for the proliferation of melanoblasts in the mouse embryo. Dev. Biol. 192, 99–107 (1997).
Mort, R. L., Hay, L. & Jackson, I. J. Ex vivo live imaging of melanoblast migration in embryonic mouse skin. Pigment Cell Melanoma Res. 23, 299–301.
Moore, K. A. et al. Rac1 is required for cell proliferation and G2/M progression. Biochem. J. 326, 17–20 (1997).
Michaelson, D. et al. Rac1 accumulates in the nucleus during the G2 phase of the cell cycle and promotes cell division. J. Cell Biol. 181, 485–496 (2008).
Gupta, P. B. et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat. Genet. 37, 1047–1054 (2005).
Uong, A. & Zon, L. I. Melanocytes in development and cancer. J. Cell Physiol. 222, 38–41 (2010).
Strizzi, L., Hardy, K. M., Kirsammer, G. T., Gerami, P. & Hendrix, M. J. Embryonic signaling in melanoma: potential for diagnosis and therapy. Lab. Invest. 91, 819–824 (2011).
Kissil, J. L. et al. Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Res. 67, 8089–8094 (2007).
Malliri, A. et al. Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. Nature 417, 867–871 (2002).
Küsters-Vandevelde, H. V. et al. Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol. 119, 317–323 (2009).
Uhlenbrock, K. et al. The RacGEF TIAM1 inhibits migration and invasion of metastatic melanoma via a novel adhesive mechanism. J. Cell Sci. 117, 4863–4871 (2004).
Becher, O. J. & Holland, E. C. Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res. 66, 3355–3358 (2006).
Sausville, E. A. & Burger, A. M. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 66, 3351–3354 (2006).
de Bono, J. S. & Ashworth, A. Translating cancer research into targeted therapeutics. Nature 467, 543–549 (2010).
Hennigan, R. F., Hawker, K. L. & Ozanne, B. W. Fos-transformation activates genes associated with invasion. Oncogene 9, 3591–3600 (1994).
Edward, M. et al. Tumour regulation of fibroblast hyaluronan expression: a mechanism to facilitate tumour growth and invasion. Carcinogenesis 26, 1215–1223 (2005).
This research was supported by an Association of International Cancer grant (AICR Grant 09-0227), Medical Research Council clinical fellowship (C.L.), National Institute of Health grant (C.J.D.), American Cancer Society Postdoctoral Fellowship (K.H.P.), and Cancer Research UK. Funding is also acknowledged from the Marie Curie Industry-Academia Partnership and Pathways programme, Target-Melanoma (www.targetmelanoma.com). Thanks to Colin Nixon and Margaret O'Prey, as well as the biological services, histology, and imaging staff at the Beatson Institute for Cancer Research in general. Thanks to Dr Peter Adams and Dr Gareth Inman for their sharing of melanoma cell lines, and to Dr Saadia Karim and Dr Ee Hong Tan for their assistance with cDNA preparation. The pcDNA3.1-myc-Tiam1 was the kind gift from Dr Angeliki Malliri of the Paterson Institute for Cancer Research, Manchester, UK. Thank you to Transnetyx Inc. for their assistance with genotyping, and also to Peter Budd for his RT–PCR work in the MRC Human Genetics Unit, Edinburgh.
The authors declare no competing financial interests.
Supplementary Figures S1–S6, Supplementary Tables S1–S4 and Supplementary Methods. (PDF 4083 kb)
Live cell imaging shows that no cell death is seen in P-Rex1−/− melanoblasts at E15.5. (AVI 10519 kb)
Live cell imaging shows that no cell death is seen in P-Rex1+/+ melanoblasts at E15.5. (AVI 10788 kb)
Live cell imaging demonstrated prominent cell death in cultures of P-Rex1+/+ cells treated with the positive control 100↘M LY294002 (AVI 4538 kb)
About this article
Cite this article
Lindsay, C., Lawn, S., Campbell, A. et al. P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat Commun 2, 555 (2011). https://doi.org/10.1038/ncomms1560
Translational Oncology (2020)
The Rho guanine nucleotide exchange factor P-Rex1 as a potential drug target for cancer metastasis and inflammatory diseases
Pharmacological Research (2020)
Proceedings of the National Academy of Sciences (2020)
Journal of Molecular Histology (2020)
Molecular Biology of the Cell (2020)